Abstract
As part of a pilot study to assess the efficacy of propranolol in the treatment of aggression in psychiatric patients, drug interactions of propranolol with other agents were estimated by blood level monitoring. In the two patients taking a standard oral dose of thioridazine, the addition of propranolol caused a threefold and fivefold increase of plasma thioridazine levels, which placed them in a potentially toxic range. Although neither patient exhibited a toxic effect, these levels may be associated with an increased risk of thioridazine-induced irreversible pigmentary retinopathy, cardiac arrhythmias, and tardive dyskinesia. The authors suggest precautionary monitoring of thioridazine plasma and other relevant levels and clinical assessments when thioridazine and propranolol are used in combination.
Citations
Dec 7, 2013·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Leslie J CloudStewart A Factor
Jan 1, 1988·International Journal of Law and Psychiatry·G N Conacher
Jan 1, 1989·Psychopharmacology·L A AdlerJ Rotrosen
Oct 1, 1990·British Journal of Clinical Pharmacology·J KallioE Iisalo
Nov 28, 2006·Expert Opinion on Drug Metabolism & Toxicology·Emilio SternieriAnna Ferrari
Jan 1, 1991·Psychosomatics·A StoudemireB S Fogel
Jun 16, 2001·Cardiology Clinics·J R Anderson, J J Nawarskas
Jan 6, 2015·Psychiatry and Clinical Neurosciences·Paul P LernerVladimir Lerner
Nov 1, 2013·Research in Developmental Disabilities·Frances WardGemma L Unwin
Jul 1, 1994·British Journal of Pharmacology·E P PrinssenA R Cools
Nov 5, 2016·Parkinsonism & Related Disorders·Jaime M Hatcher-MartinStewart A Factor
Jul 1, 1993·Journal of Child and Adolescent Psychopharmacology·D F Connor
Jan 1, 1990·Acta Psychiatrica Scandinavica. Supplementum·S G Dahl
Apr 27, 2017·Expert Opinion on Pharmacotherapy·Daniel P WitterUma Suryadevara
Nov 1, 2001·The Cochrane Database of Systematic Reviews·M CheineK Wahlbeck
Jan 13, 2004·Clinical Pharmacokinetics·Candace S BrownSamantha F Eichner
Aug 15, 2000·Therapeutic Drug Monitoring·A LlerenaJ Benítez
Sep 5, 2019·CNS Spectrums·Mazen T Elkurd, Laxman Bahroo
Jul 29, 2020·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Stewart A Factor
Nov 1, 1990·Survey of Ophthalmology·S L GerberD C Brater
Jan 13, 1999·Pediatric Clinics of North America·A P Ten EickM D Reed